Table 1.
Bodily pain |
Ocular pain |
Oral pain | |||||
---|---|---|---|---|---|---|---|
Pain interference with work quite a bit or extremely | Sharp “jabbing” needle-like pain | “Prickling” or “tingling” feeling | Having light sensitivity most or all of the time | Burning or stinging most or all of the time | Having pain/burn at night most or all of the time | Presumptive neuropathic oral pain | |
Classified as SS1 | 368 (23.9%) | 467 (30.3%) | 551 (35.8%) | 386 (25.1%) | 211 (13.7%) | 194 (12.6%) | 176 (11.4%) |
Classified as non-SS1 | 705 (38.1%) | 823 (44.3%) | 898 (48.4%) | 578 (31.2%) | 332 (17.9%) | 314 (17.0%) | 409 (22.1%) |
Sex | |||||||
Women | 1006 (31.6%) | 1215 (38.2%) | 1359 (42.7%) | 925 (29.1%) | 525 (16.5%) | 492 (15.5%) | 549 (17.3%) |
Men | 100 (32.4%) | 95 (30.7%) | 110 (35.6%) | 70 (22.7%) | 42 (13.6%) | 31 (10.0%) | 40 (12.9%) |
Race | |||||||
White | 731 (36.3%) | 906 (44.9%) | 950 (47.1%) | 633 (31.4%) | 385 (19.1%) | 351 (17.4%) | 389 (19.3%) |
Non-White | 374 (25.4%) | 402 (27.3%) | 516 (35.0%) | 361 (24.5%) | 182 (12.3%) | 171 (11.6%) | 199 (13.6%) |
Age group | |||||||
21 to 30 years | 50 (25.4%) | 60 (30.6%) | 69 (35.2%) | 47 (23.9%) | 32 (16.2%) | 29 (14.7%) | 53 (17.0%) |
31 to 45 years | 238 (29.7%) | 299 (37.2%) | 353 (44.0%) | 233 (29.1%) | 133 (16.6%) | 124 (15.4%) | 132 (17.3%) |
46 to 64 years | 617 (34.5%) | 719 (40.1%) | 789 (44.1%) | 515 (28.8%) | 308 (17.2%) | 291 (16.3%) | 320 (18.8%) |
65 years and older | 200 (28.5%) | 231 (33.0%) | 257 (36.7%) | 200 (28.5%) | 94 (13.4%) | 78 (11.1%) | 84 (12.0%) |
Site | |||||||
Argentina | 135 | 175 | 293 | 140 | 77 | 97 | 108 |
China | 38 | 34 | 33 | 36 | 9 | 1 | 23 |
Denmark | 244 | 263 | 322 | 142 | 84 | 89 | 93 |
India | 78 | 17 | 17 | 56 | 40 | 13 | 0 |
Johns | 100 | 136 | 140 | 101 | 78 | 57 | 76 |
Hopkins (US) | |||||||
Japan | 48 | 88 | 123 | 79 | 19 | 30 | 45 |
UCSF (US) | 261 | 353 | 311 | 279 | 161 | 154 | 160 |
United Kingdom | 103 | 118 | 106 | 74 | 42 | 35 | 35 |
UPenn (US) | 99 | 129 | 131 | 88 | 57 | 47 | 49 |
Abbreviations: SICCA, Sjögren’s International Collaborative Clinical Alliance; SS, Sjögren’s syndrome; UCSF, University of California – San Francisco; UPenn, University of Pennsylvania.